Cargando…

Sustained complete response to first-line immunochemotherapy for highly aggressive TP53/MDM2-mutated upper tract urothelial carcinoma with ERBB2 mutations, luminal immune-infiltrated contexture, and non-mesenchymal state: a case report and literature review

BACKGROUND: Upper tract urothelial carcinoma (UTUC) is a rare malignancy. The management of metastatic or unresectable UTUC is mainly based on evidence extrapolated from histologically homologous bladder cancer, including platinum-based chemotherapy and immune checkpoint inhibitor alone, whereas UTU...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Tianyuan, Guo, Hanxu, Xie, Jun, He, Yanyan, Che, Jianping, Peng, Bo, Yang, Bin, Yao, Xudong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328386/ https://www.ncbi.nlm.nih.gov/pubmed/37427135 http://dx.doi.org/10.3389/fonc.2023.1119343

Ejemplares similares

Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling
por: Robinson, Brian D., et al.
Publicado: (2019)

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
por: Hirose, Mitsuaki, et al.
Publicado: (2014)

Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma
por: Ognjanovic, Simona, et al.
Publicado: (2012)

MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.
por: Foulkes, W. D., et al.
Publicado: (1995)

Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an FGFR3 Mutated Aggressive Urothelial Carcinoma with Luminal-Papillary Phenotype
por: Weyerer, Veronika, et al.
Publicado: (2020)

Effects of MDM2, MDM4 and TP53 Codon 72 Polymorphisms on Cancer Risk in a Cohort Study of Carriers of TP53 Germline Mutations
por: Fang, Shenying, et al.
Publicado: (2010)

Age-Related Alterations in Immune Contexture Are Associated with Aggressiveness in Rhabdomyosarcoma
por: Gasparini, Patrizia, et al.
Publicado: (2019)

Molecular chaperones in the acquisition of cancer cell chemoresistance with mutated TP53 and MDM2 up-regulation
por: Tracz-Gaszewska, Zuzanna, et al.
Publicado: (2017)

Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition
por: Maslah, Nabih, et al.
Publicado: (2022)

Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer
por: Jindal, Tanya, et al.
Publicado: (2023)

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
por: Grote, Isabel, et al.
Publicado: (2021)

Recurrence pattern and TP53 mutation in upper urinary tract urothelial carcinoma
por: Chen, Chung-Hsin, et al.
Publicado: (2016)

The Tumor Immune Contexture of Prostate Cancer
por: Vitkin, Natasha, et al.
Publicado: (2019)

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)

Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel
por: Chrisanthar, Ranjan, et al.
Publicado: (2011)

Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations
por: Deb, S, et al.
Publicado: (2014)

Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment
por: Herter-Sprie, Grit S., et al.
Publicado: (2013)

Effects of ErbB2 Overexpression on the Proteome and ErbB Ligand-specific Phosphosignaling in Mammary Luminal Epithelial Cells
por: Worthington, Jenny, et al.
Publicado: (2017)

Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes
por: ALONSO, Juan Manuel Fernández
Publicado: (2005)

The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Sinilnikova, O M, et al.
Publicado: (2009)

Data-Driven Discovery of Immune Contexture Biomarkers
por: Schwen, Lars Ole, et al.
Publicado: (2018)

License to kill: microsatellite instability and immune contexture
por: Maby, Pauline, et al.
Publicado: (2021)

The Immune Contexture of Liposarcoma and Its Clinical Implications
por: Resag, Antonia, et al.
Publicado: (2022)

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
por: Ross, Jeffrey S., et al.
Publicado: (2018)

TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women
por: Zając, Agnieszka, et al.
Publicado: (2014)

ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia
por: Joshi, Sunil K., et al.
Publicado: (2020)

The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
por: Kirchner, M., et al.
Publicado: (2021)

Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types
por: Tazzari, Marcella, et al.
Publicado: (2018)

Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis
por: Reske, Jake J., et al.
Publicado: (2021)

CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer
por: Viotto, Davide, et al.
Publicado: (2020)

Mice with a Mutation in the Mdm2 Gene That Interferes with MDM2/Ribosomal Protein Binding Develop a Defect in Erythropoiesis
por: Kamio, Takuya, et al.
Publicado: (2016)

ATRT-08. TARGETING THE TP53-MDM2 ENHANCES RADIATION SENSITIVITY IN ATRT
por: Alimova, Irina, et al.
Publicado: (2021)

The immune contexture of hepatocellular carcinoma predicts clinical outcome
por: Foerster, Friedrich, et al.
Publicado: (2018)

Molecular pathology of the luminal class of urothelial tumors
por: Bernardo, Carina, et al.
Publicado: (2019)

Metastatic urothelial carcinoma harboring ERBB2/3 mutations dramatically respond to chemotherapy plus anti-PD-1 antibody: A case report
por: Yan, Fei-Fei, et al.
Publicado: (2022)

Vitamin D deficiency and supplementation in patients with aggressive B‐cell lymphomas treated with immunochemotherapy
por: Hohaus, Stefan, et al.
Publicado: (2017)

Impact of complete surgical resection on outcome in aggressive non‐Hodgkin lymphoma treated with immunochemotherapy
por: Schmitz, Christine, et al.
Publicado: (2020)

Unusual phylogenetic tree and circulating actionable ESR1 mutations in an aggressive luminal/HER2-low breast cancer: Case report
por: Allegretti, Matteo, et al.
Publicado: (2023)

TP53 status determines clinical significance of ERBB2 expression in ovarian cancer
por: Kupryjańczyk, J, et al.
Publicado: (2004)

Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib
por: Kancha, Rama Krishna, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_00okrn6ck8pif6pbje8ha93oe3